Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-DG lymphocytes
- Development stage
- Discontinued
- Lead developer
- Medinet
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
2-DG lymphocytes (also known as glycan-modified T lymphocytes) is an autologous T-cell therapy platform developed by Medinet Medical Institute. The technology involves the ex vivo culture of T lymphocytes in the presence of 2-deoxyglucose (2-DG), a glucose analog that interferes with N-linked glycosylation. This metabolic conditioning is designed to modify the glycan profile of the T cells, which is intended to enhance their persistence, metabolic fitness, and anti-tumor activity upon re-infusion. While Medinet initially explored 2-DG lymphocytes as a standalone therapeutic for cancer, the company has discontinued standalone development to focus on utilizing the glycan-modification process as a platform technology to improve the efficacy of CAR-T and TCR-T cell therapies.
- Other names
- glycan-modified T lymphocytes2-deoxyglucose-modified T cells
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)N-glycosylation machineryMAGEA8 (Melanoma-associated antigen 8)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on 2-DG lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2-DG lymphocytes.